Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Active, not recruiting
Retrophin, Inc.
Phase 2
2014-03-01
This study will investigate whether RE-021 (Sparsentan), a selective dual-acting receptor
antagonist with affinity for endothelin (A type) and angiotensin II receptors (Type 1), is
safe and effective in treating patients with focal segmental glomerulosclerosis (FSGS).
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Active, not recruiting
Travere Therapeutics, Inc.
Phase 2
2014-03-01
This study will investigate whether RE-021 (Sparsentan), a selective dual-acting receptor
antagonist with affinity for endothelin (A type) and angiotensin II receptors (Type 1), is
safe and effective in treating patients with focal segmental glomerulosclerosis (FSGS).
Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
Active, not recruiting
Retrophin, Inc.
Phase 3
2018-03-29
To determine the long-term nephroprotective potential of treatment with sparsentan as
compared to an angiotensin receptor blocker in patients with primary and genetic focal
segmental glomerulosclerosis (FSGS).
Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
Active, not recruiting
Travere Therapeutics, Inc.
Phase 3
2018-03-29
To determine the long-term nephroprotective potential of treatment with sparsentan as
compared to an angiotensin receptor blocker in patients with primary and genetic focal
segmental glomerulosclerosis (FSGS).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.